SeqLL

General Information
Business:

 

We are a life sciences instrumentation and services company focused on providing our tSMS™ technology to the scientific and medical community in order to accelerate the understanding of the molecular mechanisms of disease and fundamental biological processes. We have developed and offer a unique, proprietary sequencing technology platform in the multi-billion-dollar NGS market, ideally suited for emerging applications in the research and development of precision medicine and epigenetic investigations. Our technology advantage provides a simple method of quantifying DNA and RNA molecules at single molecule resolution, eliminating bias from PCR amplification or other preparation steps required by other technologies.

Industry: LABORATORY ANALYTICAL INSTRUMENTS
Employees: 12
Founded: 2014
Contact Information
Address 317 New Boston Street, Suite 210, Woburn, MA 01801, US
Phone Number (781) 460-6016
Web Address http://www.seqll.com.
View Prospectus: SeqLL
Financial Information
Market Cap $57.5mil
Revenues $0.65 mil (last 12 months)
Net Income $-3.37 mil (last 12 months)
IPO Profile
Symbol SQL
Exchange NASDAQ
Shares (millions): 1.4
Price range $5.40 - $6.40
Est. $ Volume $8.0 mil
Manager / Joint Managers WallachBeth Capital, LLC
CO-Managers -
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change